Bachem Holding AG (BCHMF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Bachem Holding AG (BCHMF) es una empresa del sector Basic Materials valorada en 0. Calificado con 46/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Bachem Holding AG (BCHMF) Exposición a Materiales y Productos Básicos
Bachem Holding AG, founded in 1971, is a global leader in peptide and oligonucleotide active pharmaceutical ingredients (APIs). The company provides comprehensive services from research to commercial application, serving pharmaceutical and biotechnology companies worldwide. With a strong focus on quality and regulatory compliance, Bachem is positioned to capitalize on the growing demand for peptide-based therapeutics.
Tesis de Inversión
Bachem Holding AG presents a notable research candidate due to its leading position in the peptide and oligonucleotide API market. The company's strong financial performance, with a profit margin of 21.4% and a gross margin of 28.7%, demonstrates its operational efficiency and pricing power. Bachem's beta of 0.98 indicates a relatively low volatility compared to the overall market. Growth catalysts include the increasing demand for peptide-based therapeutics and the company's expansion into new markets. Bachem's commitment to innovation and its focus on quality and regulatory compliance further enhance its long-term growth prospects. However, potential risks include competition from other API manufacturers and fluctuations in raw material prices. Investors should monitor Bachem's ability to maintain its market share and manage its cost structure effectively.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $5.75 billion reflects investor confidence in Bachem's growth potential.
- P/E ratio of 30.40 indicates a premium valuation, suggesting high expectations for future earnings growth.
- Profit margin of 21.4% demonstrates strong profitability and efficient operations.
- Gross margin of 28.7% highlights Bachem's ability to maintain competitive pricing and manage costs effectively.
- Dividend yield of 1.41% provides a steady income stream for investors.
Competidores y Pares
Fortalezas
- Leading position in the peptide and oligonucleotide API market.
- Strong focus on quality and regulatory compliance.
- Long-standing relationships with pharmaceutical companies.
- Vertical integration ensures a reliable supply chain.
Debilidades
- Limited diversification in therapeutic areas.
- Dependence on a relatively small number of key customers.
- Exposure to fluctuations in raw material prices.
- Geographic concentration in Europe.
Catalizadores
- Ongoing: Increasing demand for peptide-based therapeutics will drive revenue growth.
- Ongoing: Expansion into new therapeutic areas will diversify revenue streams.
- Upcoming: Potential strategic acquisitions to expand product portfolio (within 3-5 years).
- Ongoing: Strengthening partnerships with pharmaceutical companies will secure long-term supply agreements.
- Ongoing: Investments in research and development will lead to new product innovations (within 2-3 years).
Riesgos
- Potential: Competition from other API manufacturers could erode market share.
- Potential: Changes in regulatory requirements could increase compliance costs.
- Potential: Economic downturns could affect pharmaceutical spending.
- Potential: Technological advancements could render existing products obsolete.
- Ongoing: Fluctuations in raw material prices could impact profitability.
Oportunidades de crecimiento
- Expansion into new therapeutic areas: Bachem can leverage its expertise in peptide and oligonucleotide APIs to expand into new therapeutic areas, such as oncology and immunology. The global market for oncology drugs is projected to reach $286 billion by 2028, presenting a significant growth opportunity for Bachem. By developing and manufacturing APIs for these high-growth therapeutic areas, Bachem can diversify its revenue streams and enhance its long-term growth prospects.
- Increasing demand for peptide-based therapeutics: The increasing demand for peptide-based therapeutics is driving growth in the peptide API market. Peptides offer several advantages over traditional small molecule drugs, including higher specificity and lower toxicity. The global peptide therapeutics market is projected to reach $45 billion by 2027, creating a favorable environment for Bachem. By capitalizing on this trend, Bachem can increase its sales and market share.
- Strategic acquisitions: Bachem can pursue strategic acquisitions to expand its product portfolio and geographic reach. Acquiring companies with complementary technologies or market access can accelerate Bachem's growth and enhance its competitive position. For example, acquiring a company with expertise in oligonucleotide APIs would strengthen Bachem's position in this rapidly growing market segment. These acquisitions could be completed within the next 3-5 years.
- Strengthening partnerships with pharmaceutical companies: Bachem can strengthen its partnerships with pharmaceutical companies to secure long-term supply agreements and collaborative development projects. By becoming a preferred supplier for key pharmaceutical companies, Bachem can ensure a stable revenue stream and gain access to new drug development opportunities. These partnerships can also lead to the development of innovative peptide-based therapeutics, further driving Bachem's growth.
- Investing in research and development: Bachem can invest in research and development to develop new and innovative peptide and oligonucleotide APIs. By staying at the forefront of technological advancements, Bachem can maintain its competitive edge and attract new customers. This includes exploring novel peptide synthesis methods and developing APIs for emerging therapeutic targets. These R&D investments will likely yield results within the next 2-3 years.
Oportunidades
- Expansion into new therapeutic areas, such as oncology and immunology.
- Increasing demand for peptide-based therapeutics.
- Strategic acquisitions to expand product portfolio and geographic reach.
- Strengthening partnerships with pharmaceutical companies.
Amenazas
- Competition from other API manufacturers.
- Changes in regulatory requirements.
- Economic downturns affecting pharmaceutical spending.
- Technological advancements rendering existing products obsolete.
Ventajas competitivas
- Specialized expertise in peptide and oligonucleotide synthesis.
- Strong regulatory compliance and quality control.
- Long-standing relationships with pharmaceutical companies.
- Vertical integration ensures a reliable supply chain.
Acerca de BCHMF
Founded in 1971 and headquartered in Bubendorf, Switzerland, Bachem Holding AG has evolved into a prominent player in the global pharmaceutical and biotechnology industry. The company specializes in the development, production, and regulatory support of peptide and oligonucleotide active pharmaceutical ingredients (APIs). Bachem's core business revolves around providing products and services to pharmaceutical and biotechnology companies, supporting them from the research phase through clinical development and commercial application. Bachem's product portfolio includes both new chemical entities (NCEs) and generics, catering to a wide range of therapeutic needs. The company offers a comprehensive suite of services, including project management, quality and regulatory support, analytical services, and good manufacturing practice (GMP) production. Bachem's commitment to vertical integration ensures a reliable supply chain and enhances its ability to meet the evolving needs of its clients. Bachem has established a strong global presence, serving clients worldwide. The company's focus on innovation, quality, and regulatory compliance has earned it a reputation as a trusted partner in the pharmaceutical and biotechnology industries. With a workforce of 2207 employees, Bachem continues to invest in its infrastructure and capabilities to maintain its competitive edge and drive future growth.
Qué hacen
- Develops peptide active pharmaceutical ingredients (APIs).
- Produces oligonucleotide APIs.
- Provides regulatory support for peptide and oligonucleotide APIs.
- Offers commercial new chemical entities (NCEs).
- Manufactures generic peptide APIs.
- Provides project management services for pharmaceutical development.
- Offers quality control and analytical services.
- Provides GMP production services.
Modelo de Negocio
- Develops and manufactures peptide and oligonucleotide APIs for pharmaceutical and biotechnology companies.
- Generates revenue through the sale of APIs and related services.
- Offers both custom synthesis and catalog products.
- Focuses on long-term partnerships with pharmaceutical companies.
Contexto de la Industria
Bachem Holding AG operates in the chemicals industry, specifically focusing on peptide and oligonucleotide APIs. The pharmaceutical and biotechnology industries are experiencing significant growth, driven by increasing demand for novel therapeutics and personalized medicine. The competitive landscape includes companies such as ARKAF, COIHF, COIHY, FUPEF, and FUPPF, which offer similar products and services. Bachem differentiates itself through its focus on quality, regulatory compliance, and vertical integration, positioning it as a reliable partner for pharmaceutical and biotechnology companies.
Clientes Clave
- Pharmaceutical companies developing peptide-based therapeutics.
- Biotechnology companies researching and developing new drugs.
- Generic drug manufacturers requiring peptide APIs.
- Research institutions conducting peptide-related studies.
Finanzas
Gráfico e información
Precio de la acción de Bachem Holding AG (BCHMF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para BCHMF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para BCHMF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para BCHMF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de BCHMF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Anne-Kathrin Stoller
CEO
Anne-Kathrin Stoller is the CEO of Bachem Holding AG, responsible for leading the company's strategic direction and overseeing its global operations. Her background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on manufacturing and supply chain management. Prior to joining Bachem, she held leadership positions at several multinational pharmaceutical companies, where she was responsible for driving operational excellence and improving supply chain efficiency. She holds an advanced degree in Chemical Engineering.
Historial: Since assuming the role of CEO, Anne-Kathrin Stoller has focused on strengthening Bachem's market position and driving sustainable growth. Key achievements under her leadership include expanding the company's manufacturing capacity, enhancing its quality control processes, and forging strategic partnerships with key pharmaceutical companies. She has also overseen the successful launch of several new peptide APIs, contributing to the company's revenue growth and profitability.
Información del mercado OTC de BCHMF
The OTC Other tier, where Bachem Holding AG (BCHMF) trades, represents the lowest tier of the over-the-counter (OTC) market. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier often have limited financial disclosure requirements and may not meet the minimum listing standards of the major exchanges. This tier typically includes companies that are distressed, in bankruptcy, or have chosen not to comply with stricter reporting standards. Investing in OTC Other stocks carries significantly higher risks due to the lack of transparency and regulatory oversight.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases the risk of investing in BCHMF.
- Low trading volume can lead to price volatility and difficulty in exiting positions.
- The OTC Other tier has less regulatory oversight than major exchanges.
- Potential for fraud or manipulation is higher on the OTC market.
- BCHMF may not meet the minimum listing standards of major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal standing.
- Check for any red flags, such as pending lawsuits or regulatory investigations.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Bachem Holding AG is a well-established company with a long operating history.
- The company has a global presence and serves clients worldwide.
- Bachem is a leader in the peptide and oligonucleotide API market.
- The company has a strong focus on quality and regulatory compliance.
Preguntas Comunes Sobre BCHMF
¿Cuáles son los factores clave para evaluar BCHMF?
Bachem Holding AG (BCHMF) actualmente tiene una puntuación IA de 46/100, indicando puntuación baja. Fortaleza clave: Leading position in the peptide and oligonucleotide API market.. Riesgo principal a monitorear: Potential: Competition from other API manufacturers could erode market share.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de BCHMF?
BCHMF actualmente puntúa 46/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de BCHMF?
Los precios de BCHMF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre BCHMF?
La cobertura de analistas para BCHMF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en BCHMF?
Las categorías de riesgo para BCHMF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from other API manufacturers could erode market share.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de BCHMF?
La relación P/E para BCHMF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está BCHMF sobrevalorada o infravalorada?
Determinar si Bachem Holding AG (BCHMF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de BCHMF?
Bachem Holding AG (BCHMF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis is pending for BCHMF.